Epidemiological Study in Children and Adolescents With Chronic Hepatitis B (EPIC B)
A Cross-sectional, Multi-center, Epidemiological Study in Western and Asian Countries in Children and Adolescents With Chronic Hepatitis B
Sponsor: Novartis Pharmaceuticals
Listed as NCT01163240, this observational or N/A phase trial focuses on DNA Virus Infections and Digestive System Diseases and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 8 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jun 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alegre, Brazil , Alexandroupoli, Greece , Andalucía, Spain , Aquitaine, France , Athens, Greece , Aurora, United States , Bangkok, Thailand , Beijing, China , Belém, Brazil , Bhopal, India and 58 more locations